Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Nov. 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0925666/Diabetic-Foot-Ulcer-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Diabetic Foot Ulcers Therapeutics market. The report identifies the key trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Diabetic Foot Ulcers Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Scope The report provides information on the key drivers and challenges of the Diabetic Foot Ulcers Therapeutics market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Diabetic Foot Ulcers Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Diabetic Foot Ulcers Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Diabetic Foot Ulcers Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Diabetic Foot Ulcers Therapeutics market

Reasons to buy The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Diabetic Foot Ulcers Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Diabetic Foot Ulcers Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Diabetic Foot Ulcers Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Diabetic Foot Ulcer Therapeutics - Introduction 72.1 Overview 72.1.1 Diabetic Foot Ulcer Classification Systems 72.2 Epidemiology 102.2.1 Historic Epidemiology (2006-2011) 102.2.2 Forecast Epidemiology (2011-2019) 102.3 Prognosis 112.4 Etiology 112.5 Symptoms 122.6 Diagnosis 122.6.1 History 122.6.2 Neurologic Examination 122.6.3 Vascular Examination 132.6.4 Musculoskeletal Examination 132.6.5 Wound Evaluation 132.6.6 Laboratory Testing and Imaging Studies 132.7 Pathophysiology 142.8 Treatment and Management Pattern 152.8.1 Infection Control 152.8.2 Mechanical Load Relief 162.8.3 Wound Care/Debridement 162.8.4 Blood Glucose Control 162.8.5 Patient Education 172.9 Referral Pathway 172.10 GlobalData Pipeline Report Guidance 183 Diabetic Foot Ulcer Therapeutics - Market Characterization 193.1 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Global 193.2 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Global 213.3 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The US 233.4 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The US 253.5 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - France 273.6 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - France 293.7 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Germany 313.8 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Germany 333.9 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Italy 353.10 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Italy 373.11 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Spain 393.12 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Spain 413.13 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - The UK 433.14 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - The UK 453.15 Diabetic Foot Ulcer Therapeutics Market Size (2006-2011) - Japan 473.16 Diabetic Foot Ulcer Therapeutics Market Forecast (2011-2019) - Japan 493.17 Drivers and Barriers for the Diabetic Foot Ulcer Therapeutics Market 513.17.1 Drivers of the Diabetic Foot Ulcer Therapeutics Market 513.17.2 Barriers for the Diabetic Foot Ulcer Therapeutics Market 523.18 Opportunity and Unmet Need 533.19 Key Takeaway 544 Diabetic Foot Ulcer Therapeutics - Competitive Assessment 554.1 Overview 554.2 Strategic Competitor Assessment 554.3 Product Profiles for the Major Marketed Products in the Diabetic Foot Ulcer Therapeutics Market 574.4 Anti-infectives 574.4.1 Invanz (ertapenem) 574.4.2 Zosyn (piperacillin/tazobactam) 584.4.3 Zyvox (linezolid) 594.5 Wound-healing Products 604.5.1 Regranex (becaplermin) 604.6 Key Takeaway 615 Diabetic Foot Ulcer Therapeutics - Pipeline Assessment 625.1 Overview 625.2 Strategic Pipeline Assessment 625.3 Diabetic Foot Ulcer Therapeutics - Pipeline Analysis by Phase of Development 625.3.1 Diabetic Foot Ulcer Therapeutics - Phase III Pipeline 625.3.2 Diabetic Foot Ulcer Therapeutics - Phase II Pipeline 635.3.3 Diabetic Foot Ulcer Therapeutics - Phase I Pipeline 645.3.4 Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline 645.4 Diabetic Foot Ulcer Therapeutics - Pipeline by Mechanism of Action 655.5 Technology Trends Analytical Framework 675.6 Profiles of Promising Drugs 685.6.1 CVBT-141B (FGF-1) 685.6.2 Fragmin (dalteparin sodium) 695.6.3 Trafermin 705.6.4 Heberprot-P 705.6.5 HO/03/03 715.6.6 CureXcell 715.7 Key Takeaway 716 Diabetic Foot Ulcer Therapeutics - Clinical Trial Mapping 726.1 Clinical Trials by Region and Country 726.2 Clinical Trials by Phase of Clinical Development 736.3 Clinical Trials by Trial Status 746.4 Clinical Trials by Sponsors 756.5 Top Companies Participating in Diabetic Foot Ulcer Therapeutics Clinical Trials 777 Diabetic Foot Ulcer Therapeutics - Strategic Assessment 787.1 Key Events Impacting the Future Market 787.2 Future Market Competition Scenario 798 Diabetic Foot Ulcer Therapeutics - Future Players 818.1 Introduction 818.2 Company Profiles 818.2.1 Pfizer Inc. 818.2.2 Cardiovascular Biotherapeutics, Inc. 838.2.3 HealOr Ltd. 838.2.4 MacroCure Ltd. 848.2.5 Other Companies in the Pipeline 849 Diabetic Foot Ulcer Therapeutics - Licensing and Partnership Deals 8810 Diabetic Foot Ulcer Therapeutics - Appendix 8910.1 Market Definitions 8910.2 Abbreviations 8910.3 Bibliography 9010.4 Physicians and Specialists Included in this Study 9210.5 Research Methodology 9210.5.1 Coverage 9210.5.2 Secondary Research 9210.5.3 Forecasting 9310.5.4 Primary Research 9510.5.5 Expert Panel Validation 9610.6 Contact Us 9610.7 Disclaimer 96

List of Tables

Table 1: Diabetic Foot Ulcer - Wagner-Meggitt Classification 7Table 2: The University of Texas - Diabetic Wound Classification System 8Table 3: Diabetic Foot Ulcer, Global, Prevalence Population, 2006-2011 10Table 4: Diabetic Foot Ulcer, Global, Prevalence Population, 2011-2019 10Table 5: Diabetic Foot Ulcer - Risk Factors 11Table 6: Diabetic Foot Infections - Empirical Antibiotic Regimens 15Table 7: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 20Table 8: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20Table 9: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21Table 10: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22Table 11: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23Table 12: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24Table 13: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25Table 14: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26Table 15: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27Table 16: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28Table 17: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29Table 18: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30Table 19: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31Table 20: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32Table 21: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33Table 22: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34Table 23: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35Table 24: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36Table 25: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37Table 26: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38Table 27: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39Table 28: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40Table 29: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41Table 30: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42Table 31: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43Table 32: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44Table 33: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45Table 34: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46Table 35: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47Table 36: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48Table 37: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49Table 38: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50Table 39: Diabetic Foot Ulcer Therapeutics - Phase III Pipeline, 2012 62Table 40: Diabetic Foot Ulcer Therapeutics - Phase II Pipeline, 2012 63Table 41: Diabetic Foot Ulcer Therapeutics - Phase I Pipeline, 2012 64Table 42: Diabetic Foot Ulcer Therapeutics - Preclinical and Discovery Pipeline, 2012 64Table 43: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials, 2012 72Table 44: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase, 2012 73Table 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development, 2012 74Table 46: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors, 2012 75Table 47: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors, 2012 76Table 48: Diabetic Foot Ulcer Therapeutics, Global, Top Ten Companies by Phase, 2012 77Table 49: Pfizer, Inc. - Diabetic Foot Ulcer Pipeline Products, 2012 82Table 50: Cardiovascular Biotherapeutics, Inc. - DFU Pipeline Products, 2012 83Table 51: HealOr Ltd. - DFU Pipeline Products, 2012 83Table 52: MacroCure Ltd. - DFU Pipeline Products, 2012 84Table 53: Diabetic Foot Ulcer Therapeutics - Other Companies in the Pipeline, 2012 84Table 54: Diabetic Foot Ulcer Therapeutics, Licensing and Partnership Deals, 2012 88

List of Figures

Figure 1: The University of Texas - Diabetic Wound Classification System 9Figure 2: Diabetic Foot Ulcer - Pathophysiology 14Figure 3: Diabetic Foot Infections - Antibiotic Use According to Clinical Severity 16Figure 4: Diabetic Foot Ulcer - Referral Pathway 17Figure 5: Diabetic Foot Infection Therapeutics Market, Global, Revenue ($m), 2006-2011 19Figure 6: Wound-healing Therapeutics Market, Global, Revenue ($m), 2006-2011 20Figure 7: Diabetic Foot Infection Therapeutics Market, Global, Forecast ($m), 2011-2019 21Figure 8: Wound-healing Therapeutics Market, Global, Forecast ($m), 2011-2019 22Figure 9: Diabetic Foot Infection Therapeutics Market, The US, Revenue ($m), 2006-2011 23Figure 10: Wound-healing Therapeutics Market, The US, Revenue ($m), 2006-2011 24Figure 11: Diabetic Foot Infection Therapeutics Market, The US, Forecast ($m), 2011-2019 25Figure 12: Wound-healing Therapeutics Market, The US, Forecast ($m), 2011-2019 26Figure 13: Diabetic Foot Infection Therapeutics Market, France, Revenue ($m), 2006-2011 27Figure 14: Wound-healing Therapeutics Market, France, Revenue ($m), 2006-2011 28Figure 15: Diabetic Foot Infection Therapeutics Market, France, Forecast ($m), 2011-2019 29Figure 16: Wound-healing Therapeutics Market, France, Forecast ($m), 2011-2019 30Figure 17: Diabetic Foot Infection Therapeutics Market, Germany, Revenue ($m), 2006-2011 31Figure 18: Wound-healing Therapeutics Market, Germany, Revenue ($m), 2006-2011 32Figure 19: Diabetic Foot Infection Therapeutics Market, Germany, Forecast ($m), 2011-2019 33Figure 20: Wound-healing Therapeutics Market, Germany, Forecast ($m), 2011-2019 34Figure 21: Diabetic Foot Infection Therapeutics Market, Italy, Revenue ($m), 2006-2011 35Figure 22: Wound-healing Therapeutics Market, Italy, Revenue ($m), 2006-2011 36Figure 23: Diabetic Foot Infection Therapeutics Market, Italy, Forecast ($m), 2011-2019 37Figure 24: Wound-healing Therapeutics Market, Italy, Forecast ($m), 2011-2019 38Figure 25: Diabetic Foot Infection Therapeutics Market, Spain, Revenue ($m), 2006-2011 39Figure 26: Wound-healing Therapeutics Market, Spain, Revenue ($m), 2006-2011 40Figure 27: Diabetic Foot Infection Therapeutics Market, Spain, Forecast ($m), 2011-2019 41Figure 28: Wound-healing Therapeutics Market, Spain, Forecast ($m), 2011-2019 42Figure 29: Diabetic Foot Infection Therapeutics Market, The UK, Revenue ($m), 2006-2011 43Figure 30: Wound-healing Therapeutics Market, The UK, Revenue ($m), 2006-2011 44Figure 31: Diabetic Foot Infection Therapeutics Market, The UK, Forecast ($m), 2011-2019 45Figure 32: Wound-healing Therapeutics Market, The UK, Forecast ($m), 2011-2019 46Figure 33: Diabetic Foot Infection Therapeutics Market, Japan, Revenue ($m), 2006-2011 47Figure 34: Wound-healing Therapeutics Market, Japan, Revenue ($m), 2006-2011 48Figure 35: Diabetic Foot Infection Therapeutics Market, Japan, Forecast ($m), 2011-2019 49Figure 36: Wound-healing Therapeutics Market, Japan, Forecast ($m), 2011-2019 50Figure 37: Diabetic Foot Ulcer Therapeutics Market, Drivers and Barriers, 2012 52Figure 38: Opportunity and Unmet Need in Diabetic Foot Infection Therapeutics Market, 2012 53Figure 39: Opportunity and Unmet Need in the Diabetic Foot Ulcer Wound-healing Therapeutics Market, 2012 54Figure 40: Strategic Competitor Assessment of the Marketed Products in Diabetic Foot Ulcer Therapeutics, 2012 56Figure 41: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2012 65Figure 42: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Phase of Development (%), 2012 66Figure 43: Technology Trends Analytics Framework, 2012 67Figure 44: Technology Trends Analytics Framework - Description, 2012 68Figure 45: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Country, 2012 72Figure 46: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Phase (%), 2012 73Figure 47: Diabetic Foot Ulcer Therapeutics, Global, Clinical Trials by Status of Development (%), 2012 74Figure 48: Diabetic Foot Ulcer Therapeutics, Global, Overall Sponsors (%), 2012 75Figure 49: Diabetic Foot Ulcer Therapeutics, Global, Prominent Sponsors (%), 2012 76Figure 50: Diabetic Foot Ulcer Therapeutics, Global, Top Companies by Phase, 2012 77Figure 51: Diabetic Foot Ulcer Therapeutics Market, Impact Analysis, 2012 78Figure 52: Implications for Future Market Competition in the Diabetic Foot Ulcer Therapeutics Market, 2012 79Figure 53: Diabetic Foot Ulcer Therapeutics, Clinical Pipeline by Company, 2012 81Figure 54: GlobalData Market Size Estimation 93Figure 55: GlobalData Market Forecasting Model 95

Companies mentioned

Pfizer Inc.

Cardiovascular Biotherapeutics, Inc.

HealOr Ltd.

MacroCure Ltd.

To order this report:: Diabetic Foot Ulcer Therapeutics - Pipeline Assessment and Market Forecasts to 2019

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.